comparemela.com

Latest Breaking News On - Daniel claassen - Page 10 : comparemela.com

Alterity Therapeutics announces funding from Michael J Fox Foundation for ATH434 dose optimization for Parkinson s disease clinical trials

Share this article Share this article NEW YORK, Feb. 9, 2021 /PRNewswire/ Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ( Alterity or the Company ) has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson s Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson s disease (PD) based on imaging of brain iron. The funding for US$495,000 will be used to evaluate the pharmacologic profile of ATH434 in a primate model to determine the optimal dose of ATH434 in future Parkinson s disease clinical trials.  This is the second grant that Alterity has received from The Michael J. Fox Foundation to support the development of ATH434 in PD.

The Good Kind of Brainwashing

The Good Kind of Brainwashing Scientists are exploring why the glymphatic system, which helps clear waste from the brain, declines with age and whether slowing that decline can improve aging. Share This December 10, 2020 About seven years ago, Maiken Nedergaard, a neuroscientist at New York State’s University of Rochester Medical Center (URMC), and colleagues noticed a striking change in the mice they were studying. The researchers were using a microscope to spy on the animals’ brains and track the movement of the cerebrospinal fluid (CSF) that surrounds and cushions that organ. When the mice were awake, only a trickle of fluid entered the brain. But whenever the animals were unconscious either asleep or anesthetized the floodgates opened. “We saw that CSF was recycled back into the brain in anesthetized and naturally sleeping mice, but this didn’t happen in awake mice,” says Nedergaard, an investigator with the Simons Collaboration on Plasticity and the Aging Br

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.